BioPharma

Merck announced that the IAP (inhibitor of apoptosis protein) inhibitor xevinapant (formerly known as Debio 1143) plus chemoradiotherapy (CRT) markedly improved long-term efficacy outcomes in patients

First randomized trial in decades to show significant improvement in overall survival in patients with LA SCCHN, reinforcing the transformative potential...

 September 14, 2022 | News

Cytel expansion unlocks innovative clinical trial capabilities for APAC biopharma sector

This enables biotech and biopharma companies in APAC to have easier access to Cytel’s established biometrics and advanced statistical solutions. For ...

 September 07, 2022 | News

EpiEndo Commences LPS Challenge Trial for Lead Candidate EP395

 EpiEndo Pharmaceuticals (‘EpiEndo’), the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chro...

 September 01, 2022 | News

Sanyou ,KangaBio to accelerate antibody drug development and innovation

KangaBio, as a rising star biotechnology company, is committed to developing innovative prodrugs and providing innovative medicine to address unmet clinica...

 August 29, 2022 | News

Sonde Health Inks Multi-Year Partnership with Koye Pharmaceuticals

Sonde Health, a leading enterprise vocal biomarker company, has signed a multi-year agreement with Koye Pharmaceuticals, a specialty pharma organizati...

 August 25, 2022 | News

Resilience Becomes Biomanufacturing Resource Partner for California Institute for Regenerative Medicine

National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, was named b...

 August 24, 2022 | News

Sirnaomics Commence Treatment of Facial Squamous Cell Skin Cancer In Situ

 Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi t...

 August 19, 2022 | News

Bridge Biotherapeutics Receives FDA Authorization to Proceed with Phase 2 Study of BBT-877

Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotechnology company developing novel drugs for cancer, fibrosis and inflammation, announ...

 August 17, 2022 | News

WuXi ATU Announces Licensing Agreement with Janssen for TESSA™ Technology

WuXi ATU will license to Janssen its TESSA™ technology, a high-performance system that can produce 10 times more adeno-associated viral (AAV) vectors...

 August 12, 2022 | News

Monkeypox Update: FDA Authorizes Emergency Use of JYNNEOS Vaccine to Increase Vaccine Supply

U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the JYNNEOS vaccine to allow healthcare providers to use the vaccine by i...

 August 10, 2022 | News

Polyplus Introduces Transgene Plasmid Engineering Services for Optimized Viral Vector Manufacturing

Following the early 2022 acquisition of e-Zyvec, integration activities have focused on providing a deeper level of solutions support to customers. Using t...

 August 03, 2022 | News

Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy

Independent lab results demonstrate that the combination therapy retains neutralizing activity against currently dominant COVID-19 strains, as previously d...

 July 27, 2022 | News

CSafe Global Continues Investment in Cell and Gene Therapy Solutions with Addition of New Portfolio President

 CSafe Global, the innovation leader in temperature-controlled shipping solutions for the transport of life-enhancing pharmaceuticals, announced today...

 July 26, 2022 | News

Biocytogen and LiberoThera Achieve Milestone Progress in Co-Development of Fully Human GPCR Antibody Drugs

In around a year since the collaboration was established, the two parties have screened out a number of fully human therapeutic antibody clones with excell...

 July 25, 2022 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close